{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T04:04:42Z","timestamp":1758945882138,"version":"3.41.2"},"reference-count":16,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2021,1,5]],"date-time":"2021-01-05T00:00:00Z","timestamp":1609804800000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,2,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The novel Coronavirus [named severe acute respiratory syndrome-related coronavirus 2 (SARS CoV-2)] was associated with the development of acute respiratory distress syndrome (ARDS), which required mechanical ventilation in a high percentage of critically ill patients. Recent studies have highlighted a state of hypercoagulability in patients with SARS-CoV-2, leading to an increased risk of deep venous thrombosis (DVT) and pulmonary embolism (PE). The low proportion of PE-associated to DVT in COVID-19 patients may suggest that they have pulmonary thrombosis rather than embolism. There is no guideline recommendation on the treatment of massive PE in COVID-19 patients suffering from ARDS, without cardiogenic shock.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case summary<\/jats:title><jats:p>We described a series of seven SARS-COV-2 patients diagnosed with PE, in our institution, who underwent the use of systemic thrombolysis (recombinant tissue plasminogen activator) according to the standard protocol of 10\u2009mg over 15\u2009min, then 90\u2009mg over 120\u2009min.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>According to the European Society of Cardiology (ESC) severity scale, three patients had high-risk PE and four had intermediate high-risk PE. Systemic thrombolysis was found to be associated with a reduction of the Brescia-COVID Respiratory Severity Scale in five patients, recording a reduction from 3 to 1 in 2\/5 patients, and from 3 to 2 in 3\/5 patients. Furthermore, 3\/5 patients had an initial improvement of their alveolar partial pressure of oxygen (PaO2)\/fraction of inspired oxygen (FiO2) ratio ranging from a 19% (Patient 3) to a 156% improvement (Patient 6). It was also associated with a decrease of the right ventricular (RV) dysfunction and the RV\/left ventricular ratio 24\u2009h later. No major bleeding events occurred after the thrombolysis, but the overall mortality after performing systemic thrombolysis was up to 3\/7 patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Despite the low level of knowledge about the underlying pathophysiology of the COVID-19 ARDS, venous thromboembolic events, and the microvascular thrombosis, our findings suggest that in the treatment of PE with RV failure in patients with COVID-19 suffering from ARDS, without cardiogenic shock, systemic thrombolysis should be considered.<\/jats:p><\/jats:sec>","DOI":"10.1093\/ehjcr\/ytaa522","type":"journal-article","created":{"date-parts":[[2021,1,5]],"date-time":"2021-01-05T06:12:30Z","timestamp":1609827150000},"source":"Crossref","is-referenced-by-count":7,"title":["Acute pulmonary embolism and systemic thrombolysis in the era of COVID-19 global pandemic 2020: a case series of seven patients admitted to a regional hospital in the French epidemic cluster"],"prefix":"10.1093","volume":"5","author":[{"given":"John","family":"Philippe","sequence":"first","affiliation":[{"name":"Department of Cardiology and Vascular Disease, Colmar Hospital, 39 Avenue de la Libert\u00e9, 68024 Colmar, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena-Mihaela","family":"Cordeanu","sequence":"additional","affiliation":[{"name":"Department of Hypertension, Vascular Disease and Clinical Pharmacology, Strasbourg Regional University Hospital, 1, place de l'H\u00f4pital, 67091 Strasbourg Cedex, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-B\u00e9atrice","family":"Leimbach","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Vascular Disease, Colmar Hospital, 39 Avenue de la Libert\u00e9, 68024 Colmar, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phane","family":"Greciano","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Vascular Disease, Colmar Hospital, 39 Avenue de la Libert\u00e9, 68024 Colmar, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wael","family":"Younes","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Vascular Disease, Colmar Hospital, 39 Avenue de la Libert\u00e9, 68024 Colmar, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,1,4]]},"reference":[{"key":"2021021009392960500_ytaa522-B1","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/jth.14768","article-title":"Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia","volume":"18","author":"Tang","year":"2020","journal-title":"J Thromb Haemost"},{"key":"2021021009392960500_ytaa522-B2","doi-asserted-by":"crossref","first-page":"e419S","DOI":"10.1378\/chest.11-2301","article-title":"Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Kearon","year":"2012","journal-title":"Chest"},{"key":"2021021009392960500_ytaa522-B3","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1182\/bloodadvances.2018022954","article-title":"American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients","volume":"2","author":"Sch\u00fcnemann","year":"2018","journal-title":"Blood Adv"},{"key":"2021021009392960500_ytaa522-B4","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.thromres.2020.04.041","article-title":"Incidence of thrombotic complications in critically ill ICU patients with COVID-19","volume":"191","author":"Klok","year":"2020","journal-title":"Thromb Res"},{"key":"2021021009392960500_ytaa522-B5","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1161\/CIRCULATIONAHA.120.047430","article-title":"Pulmonary embolism in COVID-19 patients: awareness of an increased prevalence","volume":"142","author":"Poissy","year":"2020","journal-title":"Circulation"},{"key":"2021021009392960500_ytaa522-B6","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1159\/000194933","article-title":"Routine electrocardiography in screening for pulmonary embolism","volume":"50","author":"Petruzzelli","year":"1986","journal-title":"Respiration"},{"key":"2021021009392960500_ytaa522-B7","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/eurheartj\/ehz405","article-title":"2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)","volume":"41","author":"Konstantinides","year":"2020","journal-title":"Eur Heart J"},{"key":"2021021009392960500_ytaa522-B8","first-page":"CD1","article-title":"Calculated decisions: brescia-COVID respiratory severity scale (BCRSS)\/algorithm","volume":"22","author":"Duca","year":"2020","journal-title":"Emerg Med Pract"},{"key":"2021021009392960500_ytaa522-B9","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jcrc.2020.04.004","article-title":"Clinical presentation and initial management critically ill patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in Brescia, Italy","volume":"58","author":"Piva","year":"2020","journal-title":"J Crit Care"},{"key":"2021021009392960500_ytaa522-B10","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1056\/NEJMc2007575","article-title":"Coagulopathy and antiphospholipid antibodies in patients with Covid-19","volume":"382","author":"Zhang","year":"2020","journal-title":"N Engl J Med"},{"key":"2021021009392960500_ytaa522-B11","doi-asserted-by":"crossref","DOI":"10.1111\/jth.14893","article-title":"Coagulopathy of COVID-19 and antiphospholipid antibodies","author":"Connell","year":"2020","journal-title":"J Thromb Haemost"},{"key":"2021021009392960500_ytaa522-B12","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1111\/jth.14828","article-title":"Tissue plasminogen activator (tPA) treatment for COVID-19 associated acute respiratory distress syndrome (ARDS): a case series","volume":"18","author":"Wang","year":"2020","journal-title":"J Thromb Haemost"},{"key":"2021021009392960500_ytaa522-B13","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1097\/00003246-199012000-00021","article-title":"Prevention of adult respiratory distress syndrome with plasminogen activator in pigs","volume":"18","author":"Hardaway","year":"1990","journal-title":"Crit Care Med"},{"key":"2021021009392960500_ytaa522-B14","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1177\/000313480106700417","article-title":"Treatment of severe acute respiratory distress syndrome: a final report on a phase I study","volume":"67","author":"Hardaway","year":"2001","journal-title":"Am Surg"},{"key":"2021021009392960500_ytaa522-B15","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1053\/j.jvca.2019.05.035","article-title":"Streptokinase versus unfractionated heparin nebulization in patients with severe acute respiratory distress syndrome (ARDS): a randomized controlled trial with observational controls","volume":"34","author":"Abdelaal Ahmed Mahmoud","year":"2020","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"2021021009392960500_ytaa522-B16","doi-asserted-by":"crossref","first-page":"4903","DOI":"10.1007\/s00330-020-06865-y","article-title":"COVID-19 patients and the radiology department\u2014advice from the European Society of Radiology (ESR) and the European Society of Thoracic Imaging","volume":"30","author":"Revel","year":"2020","journal-title":"Eur Radiol"}],"container-title":["European Heart Journal - Case Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ehjcr\/article-pdf\/5\/2\/ytaa522\/36224576\/ytaa522.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ehjcr\/article-pdf\/5\/2\/ytaa522\/36224576\/ytaa522.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,10]],"date-time":"2022-12-10T14:25:42Z","timestamp":1670682342000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcr\/article\/doi\/10.1093\/ehjcr\/ytaa522\/6062702"}},"subtitle":[],"editor":[{"given":"Georg","family":"Goliasch","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]},{"given":"F Aaysha","family":"Cader","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]},{"given":"Kyriakos","family":"Dimitriadis","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]},{"given":"David","family":"Niederseer","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]},{"given":"Gemina","family":"Doolub","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]},{"given":"Fabienne","family":"Vervaat","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2021,1,4]]},"references-count":16,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2,4]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcr\/ytaa522","relation":{},"ISSN":["2514-2119"],"issn-type":[{"type":"electronic","value":"2514-2119"}],"subject":[],"published-other":{"date-parts":[[2021,2,1]]},"published":{"date-parts":[[2021,1,4]]},"article-number":"ytaa522"}}